FDA Anti-Inflammatory Division Director Will Be Celebrex Investigator Simon
Executive Summary
Celebrex clinical investigator Lee Simon, MD, will take over as director of FDA's Division of Anti-Inflammatory, Analgesic & Ophthalmic Drug Products Nov. 19.
You may also be interested in...
Merck Vioxx Detailing Should Have Addressed VIGOR Risks – FDA’s Jenkins
Merck should have included risk findings from the VIGOR study when promoting Vioxx to physicians before the data was added to labeling, FDA Office of New Drugs Director John Jenkins told a congressional hearing May 5
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
The Vioxx labeling change will allow Merck to discuss the COX-2 inhibitor's cardiovascular safety profile in the context of a rheumatoid arthritis indication and a gastrointestinal safety benefit
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
The Vioxx labeling change will allow Merck to discuss the COX-2 inhibitor's cardiovascular safety profile in the context of a rheumatoid arthritis indication and a gastrointestinal safety benefit